Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ilaria Priano"'
Autor:
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 779-791 (2023)
Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients b
Externí odkaz:
https://doaj.org/article/604e6cdc2d234a06b5347b1a01ff2632
Publikováno v:
Barcelona Respiratory Network Reviews, Vol 10, Iss 1 (2024)
Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer, currently a leading cause of cancer-related death worldwide. The development of molecular biomarkers has led to novel treatment strategies and subsequent improvement in surv
Externí odkaz:
https://doaj.org/article/d600cb5f789a42a399489af6661de192
Autor:
Kalliopi Andrikou, Tania Rossi, Alberto Verlicchi, Ilaria Priano, Paola Cravero, Marco Angelo Burgio, Lucio Crinò, Sara Bandini, Paola Ulivi, Angelo Delmonte
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 22, p 16085 (2023)
Non-small cell lung cancer (NSCLC) is one of the deadliest diseases worldwide. Tissue biopsy is the current gold standard for the diagnosis and molecular profiling of NSCLC. However, this approach presents some limitations due to inadequate tissue sa
Externí odkaz:
https://doaj.org/article/d693d366215f4a07a2ead72b936e3cc5
Autor:
Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Luca Paglialunga, Marta Rita Gatta Michelet, Daniele Lavacchi, Rossana Berardi, Giulia Mentrasti, Giulio Metro, Ilaria Birocchi, Angelo Delmonte, Ilaria Priano, Camilla Eva Comin, Francesca Castiglione, Caterina Bartoli, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundKRAS is commonly mutated in non-small cell lung cancer (NSCLC); however, the prognostic and predictive impact of each G12 substitution has not been fully elucidated. The approval of specific G12C inhibitors has modified the idea of KRAS “
Externí odkaz:
https://doaj.org/article/a435761aa6044f71a9054275e098102e
Autor:
Giuseppe Bronte, Elisabetta Petracci, Serena De Matteis, Matteo Canale, Ilaria Zampiva, Ilaria Priano, Paola Cravero, Kalliopi Andrikou, Marco Angelo Burgio, Paola Ulivi, Angelo Delmonte, Lucio Crinò
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundImmunotherapy has become the standard of care for non-small cell lung cancer (NSCLC) patients. Some patients experience primary resistance to immunotherapy. Currently, we lack a marker of resistance to immunotherapy. Myeloid-derived suppres
Externí odkaz:
https://doaj.org/article/0de34580c9a141de9b865d68fa2f0987
Autor:
Paola Ulivi, Elisabetta Petracci, Matteo Canale, Ilaria Priano, Laura Capelli, Daniele Calistri, Elisa Chiadini, Paola Cravero, Alice Rossi, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte
Publikováno v:
Biomedicines, Vol 9, Iss 10, p 1299 (2021)
Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patie
Externí odkaz:
https://doaj.org/article/60c40a933c754c659427b4be9a833db6
Autor:
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip
Publikováno v:
Scientia
Immune checkpoint inhibitors; Liquid biopsy Inhibidores del punto de control inmunitario; Biopsia líquida Inhibidors del punt de control immunitari; Biòpsia líquida Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main the
Autor:
null Caterina Carbonell, null Joan Frigola, null Nuria Pardo, null Ana Callejo, null Patricia Iranzo, null Augusto Valdivia, null Ilaria Priano, null Susana Cedrés, null Alex Martinez‐Marti, null Alejandro Navarro, null Laura Lenza, null Mireia Soleda, null Javier Gonzalo‐Ruiz, null Ana Vivancos, null Miriam Sansó, null Enric Carcereny, null Teresa Morán, null Ramon Amat, null Enriqueta Felip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53fb5ec0ecd09e6431a3b5b7a48b0577
https://doi.org/10.1002/1878-0261.13409/v2/response1
https://doi.org/10.1002/1878-0261.13409/v2/response1
Autor:
Valentina Danesi, Ilaria Massa, Flavia Foca, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Maria Ragonesi, Roberta Maltoni, Silvia Manunta, Paola Cravero, Kalliopi Andrikou, Ilaria Priano, William Balzi, Nicola Gentili, Thomas Burke, Mattia Altini
Publikováno v:
Cancers; Volume 14; Issue 18; Pages: 4481
Background: This study provides insights into the treatment use and outcomes of metastatic non-small cell lung cancer (NSCLC) patients in a real-world setting prior to and after the availability of immuno-oncology (IO) regimens in the first line (1L)
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
Autor:
Paola Ulivi, Milena Urbini, Elisabetta Petracci, Matteo Canale, Alessandra Dubini, Daniela Bartolini, Daniele Calistri, Paola Cravero, Eugenio Fonzi, Giovanni Martinelli, Ilaria Priano, Kalliopi Andrikou, Giuseppe Bronte, Lucio Crinò, Angelo Delmonte
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2352
Molecular characterization of advanced non-small-cell lung cancer (NSCLC) is mandatory before any treatment decision making. Next-generation sequencing (NGS) approaches represent the best strategy in this context. The turnaround time for NGS methodol